Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial.

Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial. Lancet. 2019 06 15; 393(10189):2404-2415.

View in: PubMed

subject areas

Aged
Antibodies, Monoclonal
Antibodies, Monoclonal, Humanized
Antineoplastic Agents
Bevacizumab
Carcinoma, Renal Cell
Disease-Free Survival
Drug Therapy, Combination
Female
Humans
Kidney Neoplasms
Male
Middle Aged
Survival Rate
Treatment Outcome

authors with profiles

Walter M. Stadler